Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 5439-5440 [2014-01979]
Download as PDF
Federal Register / Vol. 79, No. 21 / Friday, January 31, 2014 / Notices
[FR Doc. 2014–02069 Filed 1–30–14; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Notice of Meetings for Early Head
Start-Child Care Partnerships
Administration for Children
and Families, HHS.
ACTION: Notice of public meetings via
webinar and telephone call-in.
AGENCY:
This public meeting is to
obtain input on the creation of Early
Head Start (EHS)-Child Care
Partnerships that were authorized by the
2014 Omnibus Act, which was released
on January 17, 2014. The purpose of this
meeting is to provide an open door
forum for public input in order to help
the Department of Health and Human
Services as we develop future planning
activities.
To help us best develop Early Head
Start with local child care centers and
family child care providers serving lowincome infants and toddlers, this notice
invites the public to learn about
partnerships and provide information
that may assist the Agency at two public
meetings held via webinar and
telephone call-in.
DATES: Two public meetings will be
held on February 6, 2014, and February
7, 2014. The dates and times for each
meeting will be:
February 6, 2014: 4:00–5:00 p.m. EST
February 7, 2014: 4:00–5:00 p.m. EST
Registration and Additional
Information: We request that interested
persons register online with the Child
Care Communications Management
Center (CMC) to participate in one or
more meetings via either webinar or by
telephone. Interested persons may
register for the February 6 meeting at:
https://www3.gotomeeting.com/register/
905737662, or the February 7 meeting
at: https://www3.gotomeeting.com/
register/539737118.
The contact at CMC is Karen Limsi,
who can be reached by telephone at
240–399–8729 and by email at klimsi@
blhtech.com. Interested persons should
register at least the day before the
meeting in which they wish to
participate.
Each public meeting is scheduled for
one hour, but will end sooner if
participants have finished providing
input before the time period expires.
The format for the meetings is
intended to allow participants to
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:23 Jan 30, 2014
Jkt 232001
provide input and to respond to the
input provided by others. We especially
request input from entities interested in
creating partnerships.
To help interested individuals
prepare for the meetings, we invite
review of the 2014 Omnibus
Appropriations bill. The full text is set
forth at: https://www.gpo.gov/fdsys/pkg/
BILLS-113hr3547enr/pdf/BILLS113hr3547enr.pdf
Written comments may be submitted
at: EHS.CCPartnerships@acf.hhs.gov
until Midnight February 7, 2014.
SUPPLEMENTARY INFORMATION: The
expansion of EHS-Child Care
Partnerships is a key component in
President Obama’s Early Learning Plan.
These partnerships will extend the
provision of high-quality early learning
opportunities to more children from
birth to age 3. Bolstering EHS-Child
Care Partnerships promises to build a
more seamless system for providing
high-quality, full-day, full-year services
to support children’s development and
parents’ workforce needs.
These public meetings will be
primarily listening sessions for the
Agency and potentially an opportunity
for dialogue among participants. We
believe that the input received at the
public meetings will be most helpful in
providing the Agency with background
information and broadening awareness
of relevant issues of potential
partnerships between Early Head Start
grantees to develop partnerships with
local child care centers and family child
care providers serving low-income
infants and toddlers. We will not
respond to presentations during the
meetings and will not regard them as
formal comments that must be
addressed by the Agency.
Dated: January 27, 2014.
Linda K. Smith,
Deputy Assistant Secretary for Early
Childhood Development.
[FR Doc. 2014–02035 Filed 1–30–14; 8:45 am]
BILLING CODE 4184–40–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
5439
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on February 28, 2014, from
approximately 8 a.m. to 4:20 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (rm.
1503 B and C), Silver Spring, MD
20993–0002. Information regarding
special accommodations due to a
disability, visitor parking, and
transportation may be accessed at https://
www.fda.gov/AdvisoryCommittees/
default.htm; under the heading
‘‘Resources for You,’’ click on ‘‘Public
Meetings at the FDA White Oak
Campus.’’ Please note that visitors to the
White Oak Campus must enter through
Building 1.
For those unable to attend in person,
the meeting will also be webcast. The
link for the webcast is available at
https://collaboration.fda.gov/vrbpac/
Contact Person: Prabhakara Atreya or
Denise Royster, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: On February 28, 2014, the
committee will meet in open session to
hear an overview of the research
program in the Laboratory of
Respiratory Viral Diseases, Division of
Viral Products, Office of Vaccines
Research and Review, Center for
Biologics Evaluation and Research,
FDA. The committee will then discuss
and make recommendations on the
selection of strains to be included in the
influenza virus vaccine for the 2014 to
2015 influenza season.
E:\FR\FM\31JAN1.SGM
31JAN1
tkelley on DSK3SPTVN1PROD with NOTICES
5440
Federal Register / Vol. 79, No. 21 / Friday, January 31, 2014 / Notices
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: On February 28, 2014,
between approximately 8 a.m. and 9:30
a.m. and between approximately 10 a.m.
and 4:20 p.m., the meeting is open to
the public. Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 21, 2014.
Oral presentations from the public will
be scheduled between approximately
2:20 p.m. and 3:20 p.m. on February 28,
2014. Those individuals interested in
making formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before February 13, 2014. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
February 14, 2014.
Closed Committee Deliberations: On
February 28, 2014, between
approximately 9:30 a.m. and 10 a.m.,
the meeting will be closed to permit
discussion where disclosure would
constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The committee will discuss
the report of the intramural research
programs and make recommendations
regarding personnel staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
VerDate Mar<15>2010
22:14 Jan 30, 2014
Jkt 232001
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Prabhakara
Atreya or Denise Royster at least 7 days
in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 27, 2014.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2014–01979 Filed 1–30–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-day Comment
Request: National Institutes of Health
Loan Repayment Programs
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
Division of Loan Repayment, National
Institutes of Health (NIH), will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
should address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments and For Further
Information: To request more
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Steve
Boehlert, Director of Operations,
Division of Loan Repayment, National
Institutes of Health, 6011 Executive
Blvd., Room 206 (MSC 7650), Bethesda,
Maryland 20892–7650. Steve may be
contacted via email at BoehlerS@
od.nih.gov or by calling 301–451–4465.
Formal requests for additional plans and
instruments must be requested in
writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: National
Institutes of Health Loan Repayment
Programs.
Type of Information Collection
Request: Extension of a currently
approved collection (OMB No. 0925–
0361, expiration date 06/30/14).
Form Numbers: NIH 2674–1, NIH
2674–2, NIH 2674–3, NIH 2674–4, NIH
2674–5, NIH 2674–6, NIH 2674–7, NIH
2674–8, NIH 2674–9, NIH 2674–10, NIH
2674–11, NIH 2674–12, NIH 2674–13,
NIH 2674–14, NIH 2674–15, NIH 2674–
16, NIH 2674–17, NIH 2674–18, and
NIH 2674–19.
Need and Use of Information
Collection: The NIH makes available
financial assistance, in the form of
educational loan repayment, to M.D.,
Ph.D., Pharm.D., D.D.S., D.M.D., D.V.M.,
D.P.M., DC, and N.D. degree holders, or
the equivalent, who perform biomedical
or behavioral research in NIH
intramural laboratories or as extramural
grantees or scientists funded by
domestic non-profit organizations for a
minimum of 2 years (3 years for the
General Research LRP) in research areas
supporting the mission and priorities of
the NIH.
The AIDS Research Loan Repayment
Program (AIDS–LRP) is authorized by
Section 487A of the Public Health
Service Act (42 U.S.C. 288–1); the
Clinical Research Loan Repayment
Program for Individuals from
Disadvantaged Backgrounds (CR–LRP)
is authorized by Section 487E (42 U.S.C.
288–5); the General Research Loan
Repayment Program (GR–LRP) is
authorized by Section 487C of the
Public Health Service Act (42 U.S.C.
288–3); the Clinical Research Loan
Repayment Program (LRP–CR) is
authorized by Section 487F (42 U.S.C.
288–5a); the Pediatric Research Loan
Repayment Program (PR–LRP) is
authorized by Section 487F (42 U.S.C.
288–6); the Extramural Clinical
Research LRP for Individuals from
Disadvantaged Backgrounds (ECR–LRP)
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 79, Number 21 (Friday, January 31, 2014)]
[Notices]
[Pages 5439-5440]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01979]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0001]
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Vaccines and Related Biological Products
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on February 28, 2014, from
approximately 8 a.m. to 4:20 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (rm. 1503 B and C), Silver Spring, MD
20993-0002. Information regarding special accommodations due to a
disability, visitor parking, and transportation may be accessed at
https://www.fda.gov/AdvisoryCommittees/default.htm; under the heading
``Resources for You,'' click on ``Public Meetings at the FDA White Oak
Campus.'' Please note that visitors to the White Oak Campus must enter
through Building 1.
For those unable to attend in person, the meeting will also be
webcast. The link for the webcast is available at https://collaboration.fda.gov/vrbpac/
Contact Person: Prabhakara Atreya or Denise Royster, Center for
Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area). A notice in the Federal Register
about last minute modifications that impact a previously announced
advisory committee meeting cannot always be published quickly enough to
provide timely notice. Therefore, you should always check the Agency's
Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory committee meeting link, or call
the advisory committee information line to learn about possible
modifications before coming to the meeting.
Agenda: On February 28, 2014, the committee will meet in open
session to hear an overview of the research program in the Laboratory
of Respiratory Viral Diseases, Division of Viral Products, Office of
Vaccines Research and Review, Center for Biologics Evaluation and
Research, FDA. The committee will then discuss and make recommendations
on the selection of strains to be included in the influenza virus
vaccine for the 2014 to 2015 influenza season.
[[Page 5440]]
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: On February 28, 2014, between approximately 8 a.m. and
9:30 a.m. and between approximately 10 a.m. and 4:20 p.m., the meeting
is open to the public. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Written submissions may be made to the contact person on
or before February 21, 2014. Oral presentations from the public will be
scheduled between approximately 2:20 p.m. and 3:20 p.m. on February 28,
2014. Those individuals interested in making formal oral presentations
should notify the contact person and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
February 13, 2014. Time allotted for each presentation may be limited.
If the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by February 14,
2014.
Closed Committee Deliberations: On February 28, 2014, between
approximately 9:30 a.m. and 10 a.m., the meeting will be closed to
permit discussion where disclosure would constitute a clearly
unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The
committee will discuss the report of the intramural research programs
and make recommendations regarding personnel staffing decisions.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Prabhakara Atreya or
Denise Royster at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: January 27, 2014.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-01979 Filed 1-30-14; 8:45 am]
BILLING CODE 4160-01-P